A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Bladder cancer; Bladder disorders; Genitourinary disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors TesoRx
- 10 Oct 2017 Planned End Date changed from 1 Feb 2018 to 1 Sep 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Aug 2018.
- 10 Oct 2017 Planned initiation date changed from 1 Jun 2017 to 1 Dec 2017.